Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganshuang granules plus nucleos(t)ide analogues for chronic hepatitis B-related liver fibrosis
ChiCTR2400085303Phase 4Not yet recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Jun 2024
- Countries
- 1
01
Overview
Phase 4, open-label trial of Ganshuang Keli in hepatic fibrosis (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoints: Liver stiffness measurement (LSM) and Hepatitis B virus DNA quantification. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
Ganshuang Keli
03
Conditions
hepatic fibrosis
Beyond the preview
Go deeper on ChiCTR2400085303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085303.